Year: 2020
Type: review
Abstract: Reducing infarct size during a cardiac ischaemic‐reperfusion episode is still of paramount importance, because the extension of myocardial necrosis is an important risk factor for developing heart failure. Cardiac ischaemia‐reperfusion injury (IRI) is in principle a metabolic pathology as it is caused by abruptly halted metabolism during the ischaemic episode and exacerbated by sudden restart of specific metabolic pathways at reperfusion. It should therefore not come as a surprise that therapy directed at metabolic pathways can modulate IRI. Here, we summarize the current knowledge of important metabolic pathways as therapeutic targets to combat cardiac IRI. Activating metabolic pathways such as glycolysis (eg AMPK activators), glucose oxidation (activating pyruvate dehydrogenase complex), ketone oxidation (increasing ketone plasma levels), hexosamine biosynthesis pathway (O‐GlcNAcylation; administration of glucosamine/glutamine) and deacetylation (activating sirtuins 1 or 3; administration of NAD + ‐boosting compounds) all seem to hold promise to reduce acute IRI. In contrast, some metabolic pathways may offer protection through diminished activity. These pathways comprise the malate‐aspartate shuttle (in need of novel specific reversible inhibitors), mitochondrial oxygen consumption, fatty acid oxidation (CD36 inhibitors, malonyl‐CoA decarboxylase inhibitors) and mitochondrial succinate metabolism (malonate). Additionally, protecting the cristae structure of the mitochondria during IR, by maintaining the association of hexokinase II or creatine kinase with mitochondria, or inhibiting destabilization of F O F 1 ‐ATPase dimers, prevents mitochondrial damage and thereby reduces cardiac IRI. Currently, the most promising and druggable metabolic therapy against cardiac IRI seems to be the singular or combined targeting of glycolysis, O‐GlcNAcylation and metabolism of ketones, fatty acids and succinate.
DOI: 10.1111/jcmm.15180
Institutions: Amsterdam University Medical Centers, Amsterdam Cardiovascular Sciences, University of Amsterdam, UCLouvain, Cliniques Universitaires Saint-Luc, National and Kapodistrian University of Athens, Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca, Centro de Investigación Biomédica en Red, Vall d'Hebron Hospital Universitari, Aarhus University Hospital, University of Cambridge, Latvijas Organiskās Sintēzes Institūts, University of Geneva, National Institute of Chemical Physics and Biophysics, University of Rochester Medicine
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: myocardial infarction, ischemia-reperfusion injury, myocardial metabolism, metabolic therapy, glycolysis, AMPK, pyruvate dehydrogenase complex, ketone oxidation, hexosamine biosynthetic pathway, O-GlcNAcylation, sirtuins, NAD+, malate-aspartate shuttle, mitochondrial oxygen consumption, fatty acid oxidation, succinate metabolism, mitochondrial cristae, hexokinase 2, creatine kinase, ATP synthase, infarct size
Open Access status: gold
Estimated APC paid: $3,080
OpenAlex ID: W3022223885
